Company intelligence / Profile preview

Aposcience AG

Ownership: Private
Development stage: Other

Overview

Aposcience AG has developed a proprietary secretome-based regenerative therapy platform using white blood cell-derived factors. Its lead products target impaired wound healing and ischemia-related internal organ damage. The company’s topical product APO‑2 has completed a phase I trial with autologous material and is currently being evaluated as an allogeneic therapy in a phase I/II trial for hard-to-heal wounds. Internal use product APO‑1 targets acute myocardial infarction, stroke, and spinal cord injury; it has regulatory approval for phase II studies.[7]

Therapeutic areas: PulmonologyCardiovascularEndocrinologyDermatologyNeurology
Modalities: Secretome-based therapeutics (derived from peripheral blood mononuclear cells)[1][2][7]
Industry: Biotech

Drug pipeline

3 assets

APO-2

2 more assets in the full pipeline.

Partnerships

Seeking partners among companies with franchises of blood-derived products; no specific partnerships disclosed yet.[2]

Beyond the preview

Go deeper on Aposcience AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aposcience AG.